There were 1,662 press releases posted in the last 24 hours and 413,640 in the last 365 days.

The Female Health Company to Report FY2015 Operating Results on Tuesday, December 1, 2015

Investor Conference Call Scheduled for 11:15 a.m. ET

CHICAGO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- The Female Health Company (NASDAQ:FHCO), today announced that it will host an investor conference call to discuss its operating results for the fourth quarter and fiscal year ended September 30, 2015 on Tuesday, December 1, 2015 at 11:15 a.m. Eastern Time (ET).  The Company expects to report its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:15 a.m. ET on Tuesday, December 1, 2015.

A replay of the call will be available one hour after the call through 9:00 a.m. ET on Tuesday, December 8, 2015 by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the conference ID # 10076672.  After Tuesday, December 8, 2015, the replay of the call will be available on the Company's website www.fhcinvestor.com. 

“In December, following the investor conference call, we will begin an active program of meetings with our shareholders and potential investors which will continue through the balance of FY2016,” observed O. B. Parrish, Chief Executive Officer of The Female Health Company.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process.  The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.

Contacts:  
William R. Gargiulo, Jr.  231.526.1244
Michele Greco, CFO      312.595.9123

Primary Logo